Literature DB >> 15136220

Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma.

Niels Abildgaard1, Kim Brixen, Erik Fink Eriksen, Jens Erik Kristensen, Johan Lanng Nielsen, Lene Heickendorff.   

Abstract

BACKGROUND AND OBJECTIVES: Bone lesions often occur in multiple myeloma (MM), but no tests have proven useful in identifying patients with increased risk. Bone marker assays and bone densitometry are non-invasive methods that can be used repeatedly at low cost. This study was performed to evaluate these methods in predicting bone events in MM patients. DESIGN AND METHODS: Thirty newly diagnosed MM patients were enrolled. Serum C-terminal telopeptide (ICTP) and urinary N-terminal telopeptide (NTx) of collagen I were measured for assessment of bone resorption, and serum C-terminal (PICP) and N-terminal (PINP) propeptides of procollagen I, bone-specific alkaline phosphatase, and osteocalcin were measured to estimate bone formation. Dual energy X-ray absorptiometry (DEXA) was used to assess bone mineral density (BMD) of the lumbar spine, hip, and whole body. Serum and urine samples were collected every 6 weeks, DEXA-scans performed every 3 months, and skeletal radiographs were done every 6 months as well as when indicated.
RESULTS: Serum ICTP and urinary NTx were predictive of progressive bone events. Markers of bone formation, bone mineral density assessments, and M component measurements were less informative. In Cox analysis, ICTP showed the highest predictive value, but should be replaced with NTx in patients with nephropathy. Pretreatment low lumbar BMD was predictive of early vertebral fractures. INTERPRETATION AND
CONCLUSIONS: Sequential DEXA-scans showed heterogeneous local BMD changes, and our data do not support routine use of sequential DEXA-scans. However, lumbar DEXA-scans at diagnosis can identify patients with increased risk of early vertebral collapses. Sequential analyses of serum ICTP and urinary NTx are useful for monitoring bone damage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136220

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  11 in total

1.  Tumorigenic potential and disease manifestations of malignant B-cell variants differing in their fibronectin adhesiveness.

Authors:  Liat Nadav; Vyacheslav Kalchenko; Meir Max Barak; Elizabeth Naparstek; Benjamin Geiger; Ben-Zion Katz
Journal:  Exp Hematol       Date:  2008-08-09       Impact factor: 3.084

2.  Predicting multiple myeloma disease activity by analyzing natural calcium isotopic composition.

Authors:  G W Gordon; J Monge; M B Channon; Q Wu; J L Skulan; A D Anbar; R Fonseca
Journal:  Leukemia       Date:  2014-06-12       Impact factor: 11.528

3.  Soluble molecules and bone metabolism in multiple myeloma: a review.

Authors:  Gabriele Zoppoli; Enrico Balleari; Riccardo Ghio
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

4.  Osteolytic lesions marker in multiple myeloma.

Authors:  Irena Djunic; Ivo Elezovic; Milica Marinkovic; Nada Suvajdzic-Vukovic; Dragica Tomin; Gradimir Jankovic; Jelena Bila; Darko Antic; Ana Vidovic; Borka Neskovic; Dragica Nikolic-Vukosavljevic
Journal:  Med Oncol       Date:  2010-02-02       Impact factor: 3.064

5.  The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club.

Authors:  E Cavalier; P Bergmann; O Bruyère; P Delanaye; A Durnez; J-P Devogelaer; S L Ferrari; E Gielen; S Goemaere; J-M Kaufman; A Nzeusseu Toukap; J-Y Reginster; A-F Rousseau; S Rozenberg; A J Scheen; J-J Body
Journal:  Osteoporos Int       Date:  2016-03-30       Impact factor: 4.507

6.  Sotatercept in patients with osteolytic lesions of multiple myeloma.

Authors:  Kudrat M Abdulkadyrov; Galina N Salogub; Nuriet K Khuazheva; Matthew L Sherman; Abderrahmane Laadem; Rachel Barger; Robert Knight; Shankar Srinivasan; Evangelos Terpos
Journal:  Br J Haematol       Date:  2014-03-21       Impact factor: 6.998

Review 7.  Advanced Imaging of Multiple Myeloma Bone Disease.

Authors:  Barry G Hansford; Rebecca Silbermann
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-07       Impact factor: 5.555

Review 8.  Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview.

Authors:  Antonella Argentiero; Antonio Giovanni Solimando; Oronzo Brunetti; Angela Calabrese; Francesco Pantano; Michele Iuliani; Daniele Santini; Nicola Silvestris; Angelo Vacca
Journal:  Cancers (Basel)       Date:  2019-08-29       Impact factor: 6.639

9.  Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis.

Authors:  Thomas Lund; Niels Abildgaard; Thomas L Andersen; Jean-Marie Delaisse; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-01-13       Impact factor: 2.997

Review 10.  Myeloma bone disease.

Authors:  Ralph D Sanderson; Joshua Epstein
Journal:  J Bone Miner Res       Date:  2009-11       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.